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Summary The all-time low incidence of measles in Portugal in the recent years, raises ques-
tions regarding whether the disease has been eliminated, the role of recent control measures,
and the epidemiological consequences of the rise in the proportion of newborns to vaccinated
mothers, as opposed to those born to mothers who acquired immunity by natural infection.
We estimate the vaccination coverage against measles in Portugal on a cohort-by-cohort basis,
and incorporate this information into an age-structured seasonally-driven mathematical model
aimed at reproducing measles dynamics in the past decades. The model reproduces docu-
mented trends in disease notiﬁcations and the serological proﬁle of the Portuguese population,
as estimated by a recent National Serological Survey. We provide evidence that the effectiveRreproduction number (Re) of measles has been driven below 1 in Portugal, and that sustainedmeasles elimination is crucially dependent upon the maintenance of a high (>95%) coveragewith the MMR I vaccine in the future. If the vaccination coverage decreases to levels around
90% the anticipation of the ﬁrst dose of the MMR I from 15 to 12 months of age, will ensure that
Re remains below 1.
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ver the past 5 years, the incidence of measles in Portugal 28
as declined to an all-time low. Between 2002 and 2005, 29
total of 24 suspected cases of measles were notiﬁed to 30
he Portuguese authorities [1], corresponding to an annual 31
ncidence of <0.6 cases per million individuals. This follows 32
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strategy put into place against measles that included a
wo-year catch-up vaccination campaign (1998—1999), the
nticipation of the age of the second dose of the measles-
umps-rubella vaccine (MMR II) from 11—13 to 5—6 years
ld (since January 2000), and the maintenance of a high
evel of immunization coverage by routine vaccination, as
ocumented by the National Serologic Survey [2] conducted
n 2001—2002. Portugal thus appears to be on track to fulﬁll
he 2010 measles elimination target set by WHO [3].
Nevertheless the high transmissibility of measles poses
signiﬁcant challenge to any attempt to eliminate it.
ecently, measles re-emerged in the European Region of the
HO, including countries that had already achieved good
evels of measles control [4—8]. Most cases occurred in non-
mmunized individuals that either failed vaccination or were
oo young to be vaccinated, usually children younger than
5 months of age [4—6]. The building of a susceptible pool
f these infants is of particular concern, as a disproportion-
te number of measles-associated deaths occur in children
nder the age of routine immunization [9,10].
The resurgence of measles in the United States of
merica, between 1989 and 1991, provides an outstanding
xample. During this epidemic, the epidemiology shifted
ramatically from school-aged to preschool children [11].
nfants below 15 months of age were not yet eligible for
accination and, despite comprising only 2% of the gen-
ral population, accounted for 24% of the 55,622 cases
eported. Sixty percent of measles related deaths occurred
mong preschool children [11,12]. Other examples of out-
reaks among the very young have been recently reported
n Europe. In a cluster of 580 cases in south London,
etween December 2001 and May 2002, 40% were aged
nder 12 months [4]. At La Rioja, Spain, where vaccine
overage was estimated to be 96.3% at 15 months of age,
3 out of the 18 conﬁrmed cases of measles that took
lace in 2005—2006, were in children aged under 15 months
5].
Previous studies have indicated that infants whose moth-
rs acquired immunity to measles by vaccination, have
ncreased susceptibility to clinical measles, as compared to
nfants born to mothers who have been exposed to the wild
irus [12]. This is in agreement with evidence for a faster
eroprevalence decay of passively acquired maternal anti-
odies in unvaccinated infants born to vaccinated mothers,
s compared to those whose mothers had measles [13—16].
s the proportion of mothers who have been vaccinated
ncreases over the years in the current vaccination era, so
oes the proportion of children who should respond to the
easles vaccine at younger ages [14]. As a consequence,
n January 1994 the routine age for MMR I vaccination in
he USA was lowered from 15 months to between 12 and
5 months [17]. Recently, concern has also been raised
n Europe regarding this issue [3,5] and, accordingly, the
ortuguese authorities are contemplating to anticipate the
ge of MMR I from 15 to 12 months old by the time the
roportion of newborns from vaccinated mothers exceeds
0%. U
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We investigate the current epidemiological situation
f measles in Portugal, focusing on whether recent
accination strategies created conditions for measles elim-
nation. We estimate vaccination coverage along cohorts
nd input this information into an age-structured PSEIR P
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protected-susceptible-exposed-infected-recovered) math-
matical model, where the ‘‘protected’’ category keeps
rack of newborns from vaccinated, unvaccinated non-
usceptible, and unvaccinated susceptible mothers.
The model is aimed at revealing the most important
spects of measles dynamics in Portugal in the recent past,
ut we also investigate how future scenarios of measles
ontrol are effective at ensuring sustained measles elim-
nation. In particular, we show that, for a narrow region
f vaccination coverage around 90%, the anticipation of
he recommended age for the ﬁrst dose of the vaccine,
rom 15 to 12 months, is crucial to maintain the effective
eproduction number below 1 and thus, preventing measles
utbreaks. For higher levels of vaccination coverage how-
ver, it contributes to hamper the building of a pool of
usceptible children younger than vaccination age, decreas-
ng the likelihood that imported cases result in small clusters
mong that age group. We also show that the success in sus-
aining measles elimination is crucially dependent on the
aintenance of a very high vaccination coverage with the
MR I.
ata and methods
ast-vaccination strategies and vaccine data
accination against measles in Portugal started in 1973, with
major catch-up campaign aimed at children under 10 years
ld. The campaign lasted until 1977 with 650,000 vaccines
eing delivered throughout. Routine vaccination started in
974, with a single-dose at 15 months of age. In 1987, the
onovalent measles vaccine was replaced by the MMR I and,
n late 1990, the second dose (MMR II) was introduced in
he routine calendar for children between 11 and 13 years
ld. In 1998, the forecast of an upcoming measles outbreak
rom time series analysis [18] prompted health authorities
o conduct a two step catch-up campaign for unvaccinated
hildren. This second campaign targeted ages 15—59 months
n 1998 and ages 6—18 years old in 1999. In 2000, further
nalysis [19] led authorities to anticipate the recommended
ge of the MMR II to 5—6 years old.
The number of vaccines delivered every year, has been
ublished by the Portuguese National Institute of Statistics
20] with varying age groups over time. Previous attempts
o estimate vaccination coverage in Portugal [21,22], were
ased upon the ratio between vaccines given during the
econd year of life and estimates of the standing popu-
ation at the same age. By not following cohorts, these
stimates miss the combined impact of campaigns with rou-
ine vaccination and disregarded vaccination with the MMR
I.
In order to estimate vaccination coverage along cohorts,
e have separated vaccines by age, following a procedure
imilar to the one by Fine and Clarkson [23]:
. Vaccines given to age group 0—4 years old:JVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
In years 1974—1977, 1979—1982, and 1986—1990, 147
there is information available on the number of vac- 148
cines by age. These records show that before 1988, less 149
than 80% of the vaccines were given between 12 and 150
24 months of age. After 1989, the percentage given 151
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Table 1 Proportional distribution per year of the 650,000
vaccines given during the 1973—1977 vaccination campaign
Scenario Vaccine distribution
1973 1974 1975 1976 1977
1 2/7 2/7 1/7 1/7 1/7
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2 5/15 4/15 3/15 2/15 1/15
3 4/8 1/8 1/8 1/8 1/8
at 12—24 months rose above 80%, indicating a ten-
dency to vaccinate closer to the recommended age of
15 months. Whenever necessary, we have thus disaggre-
gated vaccines by age, in years before 1989, following
the percentages 2.6%, 65.8%, 18.4%, 7.9% and 5.3% for
ages 0, 1, 2, 3, and 4 years old, respectively. In 1989 and
later years, we have used the percentages 2.6%, 89.5%,
2.6%, 2.6% and 2.6% for the same ages.
2. Vaccines given to age group 5—10 years:
We have assumed that the majority of children were
vaccinated between 5 and 7 years, as they are required
to present the vaccination booklet at registration for the
ﬁrst school grade. Vaccines were thus distributed by age,
attributing a weight of 2/8 to ages 5, 6, and 7 and 1/8 to
ages 8 and 9.
3. Vaccines given to age group 11—16 years old were uni-
formly distributed by ages. It is assumed that these ages
received MMR II, whereas ages 1—10 received MMR I.
There is no information available regarding the break up
of the 650,000 vaccines given in the 1973—1977 campaign
by year and age, so we have considered three plausible sce-
narios of vaccine distribution throughout this period which
are described in Table 1.
Vaccination coverage
Vaccination coverage with the MMR I is the cumulative
proportion of vaccinated individuals along each cohort, esti-
mated as follows,
VC =
10∑
i=0
[vi − vini di]
N0 −
10∑
i=0
di
(1)
For each cohort, the number of vaccines, vi, given to chil-
dren in yearly age groups i = 0, 1, 2, . . . 10, was added up
to give the total number of vaccinees at age i. As the
cohort ages, its initial number of individuals, N0, dimin-
ishes because of deaths, di. We denote the number of
children alive at age j by nj = N0 −
∑j
i=0di. A proportion
of deaths vi
ni
di, is subtracted from those who were vacci-U
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nated, assuming that the likelihood of dying is independent
of the vaccination status. To estimate the vaccination cov-
erage with the MMR II, Eq. (1) was adapted to ages between
11 and 16 years old.
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pidemiological model
asic structure
he transmission dynamics of measles was modelled by
deterministic PSEIR (protected by maternal antibodies,
usceptible, exposed, infectious, recovered) age-structured
odel [24,25], where the protected compartment has been
plit into two, one for newborns to vaccinated mothers and
nother for newborns to mothers who became immune by
ontact with the wild virus; newborns to susceptible mothers
nter directly into the susceptible compartment. Individu-
ls are classiﬁed into cohorts, where each cohort consists of
hildren born at the beginning of the school year (starting
st of October). The age of all children is incremented by
ne year at the end of the school year (30th September). The
ean number of births per year, life expectancy and the fer-
ility function used in the model (Table 2), were estimated
rom Portuguese data [26,27]. Epidemiological parameters
Table 2), were drawn from the literature [28]. Markowitz et
l. [14] demostrated that 98% of children born from vacci-
ated mothers had a serological response to measles vaccine
t 12 months of age, compared with 83—90% of children born
rom naturally immune mothers. Assuming an exponential
ecay of antibodies, these percentages can be accounted
y, respectivelly, a maternal mean antibody duration of,
pproximately 3 and 6 months.
The model keeps track of daily changes between epi-
emiological compartments within each cohort, due to
isease transmission, disease recovery, and vaccination. The
atter was input based on our estimates of vaccination cov-
rage along cohorts, following the methodology described
bove, and attempting the three campaign scenarios in
able 1. Mathematically, the model is represented by a set
f ordinary differential equations (Appendix A), one for each
ompartment.
ransmission rates
he model incorporated age-dependent force of infection
nd seasonality driven by the school calendar. The contact
atterns of four age groups (0—4, 5—10, 11—20, >20) are
escribed by the ‘‘Who Acquires Infection From Whom’’
WAIFW) matrix [28] presented in the Appendix A. These
ge groups roughly correspond to the main school grades in
ortugal: preschool (0—4 years old), primary school (5—10
ears old), secondary school (11—20 years old), and adults.
he structure of the matrix embodies the opinion that the
ain route of transmission for measles is whithin the school
layground or classroom. There is a unique coefﬁcient, b(2),
escribing the presumed high transmission among suscepti-
le and infectious individuals of age group 5—10 and other
oefﬁcients, b(1) and b(3), for contacts among individuals
ess than 20 years old while the older age group is described
s likely to acquire infection from a wider range of age
roups. This structure was used in Schenzle [24] and in
nderson and May [28] to model measles notiﬁcation data
n England and Wales before the introduction of mass vac-JVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
ssumed that the contact rate within the 5—10 age group 246
epended upon the school calendar. Transmission attained 247
maximum in school days and a minimum in weekends and 248
olidays. We have also assumed that the contact rate in the 249
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Table 2 Values of demographic and epidemiological parameters used in the model
Parameter Symbol Value References
Number of newborns 126,666 per year [26,27]
Life expectancy 75 years [26,27]
Mean duration of latency 1/ 8 days [28,29]
Mean duration of infectiousness 1/ 5 days [28,29]
Mean duration of passive immunity due to measles infection
Mean duration of passive immunity due to vaccine-induced immun
5—10 years old group was always equal or greater than that250
in the 0—4 years old group.251
In Portugal, notiﬁcation reports of measles started in252
1987, 14 years after the beginning of mass vaccination, ren-253
dering the direct estimation of the force of infection from254
notiﬁcations unfeasible. To circumvent this problem, we255
have initially approximated the transmission rates by numer-256
ical values derived from estimates of the basic reproduction257
numbers used to characterize the transmission dynamics258
of measles in England and Wales (case 1 in Table 3) [24].259
The age-speciﬁc basic reproduction number, R0,i, is deﬁned260
as the average number of secondary infections (in all age261
classes) generated by one primary case in the ith age class,262
when the population is wholly susceptible [28]. With this263
deﬁnition,264
R0,i =
∑
j=1
N0

ˇji(aj − aj−1) (2)265
where N0 is the number of newborns,  is recovery rate from266
the infectious state, and the aj are bounds on discrete age267
classes. The transmission coefﬁcients ˇji are the elements268
of the WAIFW matrix, and represent the probability per unit269
time of an effective contact of individuals in age group i270
with individuals in age group j. Eq. (2) can be simpliﬁed271
by limiting the number of distinct elements in the WAIFW272
matrix, namely, by setting it symmetric, such that ˇji = ˇij273
and assuming equal contact rates among selected age groups274
[24,28].275
Assuming that the pattern of R0 variation with age has not276
been too different across European countries [31], we have277
adopted the R0,k values 4.5, 9.0, 3.5, and 3.0, respectively,278
for preschool children, primary school children, adoles-279
Table 3 Values for R0,k and the corresponding bk values
Case R0,k bk(10−6)
1 a 4.5, 7, 3.5, 3 0.26, 1.05, 0.10, 0.063
2 4.5, 5, 3.5, 3 0.26, 0.41, 0.10, 0.063
3 4.5, 12, 3.5, 3 0.26, 2.63, 0.10, 0.063
4 4.5, 10, 3.5, 3 0.26, 1.99, 0.10, 0.063
5 4.5, 8, 3.5, 3 0.26, 1.36, 0.10, 0.063
6 6, 9, 3.5, 3 0.49, 1.44, 0.10, 0.06
7 b 5, 9, 3.5, 3 0.33, 1.60, 0.10, 0.06
8 7, 9, 3.5, 3 0.65, 1.28, 0.10, 0.06
9 6, 9, 5, 3 0.37, 1.32, 0.22, 0.06
10 4.5, 9, 4, 3 0.22, 1.64, 0.14, 0.06
a Base line values given in Schenzle [24].
b Parameter values selected for Portugal.
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ity 1/p 3 months [14,30]
ents, and adults, which have been used in Schenzle [24]
or England and Wales. We have then calculated four corre-
ponding numerical values for the transmission parameters,
k, that satisfy that baseline R0,k vector. Furthermore, we
ave considered nine additional plausible R0,k sets (Table 3)
hat are slight modiﬁcations of the baseline vector, gather-
ng a total of ten possible R0,k sets that were used to access
he sensitivity of model results.
The model was run for each R0,k set until reaching equi-
ibrium. Those sets yielding sustained 2—3-year epidemic
ycles, typical of measles in absence of mass vaccination
32], were then selected. The vaccination campaign was
llowed to start both in epidemic and non-epidemic years.
odel validation
he model was validated by several criteria. First, transmis-
ion parameters were selected to yield sustained incidence
scillations with an inter-epidemic period of 2—3 years.
econd, measles incidence simulated by the model was
ompared with case-notiﬁcations available in Portugal for
he period 1987—1997; attention was particularly directed
o (i) the model’s ability to reproduce three epidemic
eaks known to have occurred in 1984—1985, 1988—1989,
nd 1993—1994, and (ii) the ability to reproduce the
ve-fold increase observed in case-notiﬁcations, between
re-epidemic and epidemic peaks. Third, the distribution of
eropositives by age predicted by the model in 2001, was
ompared with the results of the National Serologic Survey
onducted in Portugal for 2001—2002. Fourth, seasonality
oefﬁcients (mean deviation between monthly incidence
nd overall mean) predicted by the model were compared
ith case-notiﬁcation seasonality. Finally, we have com-
ared the incidence by age in epidemic years predicted
y the model with notiﬁcations by age in the 1988—1989
nd 1993—1994 epidemics. The selection of epidemic years
or comparison is meant to avoid the noise associated with
nder-reporting and false positives, both known to be more
ervasive in inter-epidemic periods [33].
ffective reproduction number
he effective reproduction number, Re, is deﬁned as the
ctual mean number of secondary cases produced by a typ-
cal infectious individual in the population. If measles is in
ndemic equilibrium, one expects Re ≈ 1, as each case pro-
uces on average one other case, whereas if the infectionJVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
s driven to elimination, one expects Re to be consistently 323
elow 1. Mathematically, Re is the largest eigenvalue of the 324
ollowing matrix [34,35]: 325
iag(S)G (3) 326
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Figure 1 Number of vaccines against measles given between
1974 and 2000 (dashed lines) and number of newborns per year
over the same time period (full line). We assume that ﬁrst dose
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(Table 3), when combined with scenario 1 of the vaccination 388
campaign (Table 1), produced incidence patterns resembling 389
measles epidemiology between 1987 and 1998 (Fig. 3). There 390
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where Diag(S) is a matrix with the proportion of suscepti-
ble per age group in the main diagonal and G = [gij] is the
so-called next generation matrix. The elements gij can be
decomposed as
gij = ˇij

(4)
where  is the instantaneous rate of recovery from infec-
tiousness, 1/ is the average duration of the infectious
period (with type I mortality), and ˇij is the transmission
coefﬁcient. In the simulations, Re was computed on a daily
basis, by building the (4 × 4) matrix in Eq. (3) and extracting
its largest eigenvalue.
Control scenarios
We have examined the likely contribution of the 1998—1999
catch-up campaign to the elimination of indigenous measles
in Portugal, and simulated realistic scenarios of measles
control, in order to determine which are likely to sustain
measles elimination. In particular, we have explored the
ongoing vaccination coverage with the MMR I, either at 90%
or 95%, assuming that individuals effectively immunized by
vaccination stay lifelong immune. Vaccination coverage with
the MMR II was simulated at 10% and 70% of those that
remained susceptible. We have also examined how impor-
tant it is to anticipate the recommended age of the MMR I
from 15 to 12 months of age. Vaccine efﬁcacy is assumed to
be of 95%.
Results
Vaccination coverage
The number of vaccines against measles given in Portugal
increased over the years, since vaccination begun in 1973
(Fig. 1), with peak uptakes observed shortly after 1985,
1989, and 1994, probably a reaction to the epidemic out-
breaks that took place in those years. The number of MMR
II doses decreased since its introduction (Fig. 1). Neverthe-
less, as the effort to accurately target the recommended
11—13 year olders improved, estimates of MMR II coverage at
12 years old increased from about 20% in the 1979 cohort to
above 40% in subsequent cohorts (Fig. 2). It has not been pos-
sible to determine what percentage of those that received
the MMR II were already immune by either vaccination or
infection.
In the years following the introduction of mass vaccina-
tion, the number of vaccines was much smaller than the
number of newborns, but this ratio changed around 1989
(Fig. 1). Accordingly, at 2 years of age the vaccination cov-
erage of the 1975 cohort was around 20%, but coverage
gradually increased in subsequent cohorts, reaching 80% in
the 1989 cohort and remaining above this value thereafter.
Children in cohorts born before 1987 were vaccinated at ages
older than recommended and consequently, at 7 years of
age, the cumulative coverage of these cohorts almost dou-U
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bled the cumulative coverage at 2 years of age (Fig. 2).
Vaccination coverage with the MMR II, as accessed at 12
years of age, remained at low levels, varying between 20%
and 60% between 1991 and 2000 (cohorts 1979—1988). An
unknown proportion of individuals were already immune by
F
t
y P
ROaccines are given to children less then 11 years old and secondose vaccines are given to children between 11 and 16 yearsld.
he time they took the MMR II, so the additional coverage
f susceptibles brought about by the MMR II should be yet
ower.
ncidence and model validation
he simulation results were very sensitive to the set of
asic reproduction numbers adopted. Only the set number 7JVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
igure 2 Vaccination coverage of the 1974—1998 cohorts with
he MMR I at 2 and 7 years old (bars), and with the MMR II at 12
ears old (dark line).
D 
PR
OO
F
ARTICLE IN PRESS+ModelJVAC 7879 1—10
6 A.C. Paulo et al.
Figure 3 Incidence of measles per month for the period
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Figure 4 (A) Distribution of measles cases by age class from
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etween 1967 and 1998, resulting from the model (full line),
nd from notiﬁcations multiplied by a factor of 7 (dashed line).
he arrow points the beginning of mass vaccination.
ions when the latter are ampliﬁed by a factor of seven.
his can be considered an estimate of the degree of sub-
otiﬁcation of measles and it is coincident with a previous
stimate of the sub-notiﬁcation of chickenpox in Portugal
36].
The simulated ratio between incidence in pre-epidemic
nd epidemic peaks, both in 1989—1990 and in 1993—1994,
as 1:6.8. This is not too different from the 1:5.5 ratio cal-
ulated directly from measles notiﬁcations. The model was
lso able to reproduce the distribution of measles cases by
ge group, as observed in a comparison with notiﬁcations of
he 1988—1989 (11,791 notiﬁcations) and 1993—1994 (3230
otiﬁcations) epidemics (Fig. 4 A), and in a comparison with
he distribution of seropositives estimated by the National
erological Survey (NSS) conducted in 2001—2002 (Fig. 4B).
he NSS was based on a sample of 851 individuals older
han 2 years old, attending a network of health-care clinics
resent throughout the 18 districts of mainland Portugal.
mpact of vaccination strategies
ig. 5 presents the changing epidemiology of measles by age
0—15 years old), between 1967 and 2000, as predicted by
he model. Before mass vaccination, the susceptible pool
as concentrated in 0—5 year olders, with the majority of
eople being already immune by 7—8 years old. Oscillations
n the pool of susceptibles, due to the accumulation of sus-
eptible newborns and their consumption by epidemics, is
epresented in the lower part of Fig. 5 by the widening and
arrowing of the whitish spots. The grey spikes extending to
he top right in the ﬁgure, represent cohorts with higher pro-
ortions of susceptibles within the 0—15 age range. With the
ntroduction of mass vaccination in 1974, the whitish areasU
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ecrease gradually and susceptibility concentrated increas-
ngly in newborns too young to be vaccinated.
In the simulations, the effective reproduction number
xhibit damped oscillations around 1 until 1998 (Fig. 6). We
e
m
b
l001—2002, was based on a sample of 851 individuals older than
years old, attending a network of health-care clinics present
hroughout the 18 districts of mainland Portugal.
nd that in absence of the 1998—1999 catch-up campaign,
e would not have decreased enough to avoid a return to
and measles would have remained endemic in Portugal.
he model shows how the 1998—1999 campaign pulled Re
o values around 0.4 in 2000—2001 and how its evolution in
he future depends on the vaccination coverage achieved
Fig. 6). Once Re became systematically lower than 1, an
MR I coverage < 90% is too low to guarantee Re < 1, given
n MMR II coverage of only 10% of those who are susceptible
t 6 years old (either due to MMR I failure or because they
ere never vaccinated or infected). In spite of the progress
o far made to control measles, a very high vaccination cov-JVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
rage (>95%) with the MMR I is still the most effective way to 439
aintain herd immunity in Portugal to a level where Re stays 440
elow 1. The simulations also indicate that these results are 441
ittle inﬂuenced by whether the recommended age for the 442
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Figure 7 Relation between the effective reproduction num-
ber and different levels of vaccination coverage when the age
f
m
w
t 449
M 450Figure 5 Evolution between 1967 and 2000 of the proportion
of immune individuals since birth to 15 years old (simulate by
the model).
MMR I remains at 15 months or is anticipated to 12 months
of age (Fig. 7) unless vaccination coverage is near 90%.UN
CO
RR
EC
TE
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The ratio between newborns to vaccinated mothers ver-
sus newborns to naturally immune mothers has been rising
steeply since the late 1980s (Fig. 8). We estimate that by
2011 it should hit 50%, an estimate that is little sensitive
Figure 6 Simulated evolution of the effective reproduction
rate Re for measles in Portugal. Values of Re from 1967 to 2000,
based on estimates of real vaccination coverages in the model.
The simulation shows that in absence of the 1998—1999 catch-
up campaign, Re would have not remained well below 1. After
2000, Re is simulated under different vaccination scenarios. Full
line curves follow the catch-up campaign and represent differ-
ent coverages with MMR I and II, respectively, (a) 9% and 10%, (b)
95% and 10%, (c) 95% and 70%. Dashed lines illustrate the same
three scenarios, from top to bottom, if the catch-up campaign
had not taken place.
9 451
n 452
m 453
t 454
A 455
t 456
9
a
d
v
F
o
c
c P
ROor MMR I is 18 months (full line), 15 months (dashed line) or 12onths old (dotted line). Simulations corresponds to the casehere 60% of newborns are born to vaccinated mothers.
o assumptions concerning vaccination coverage with the
MR I so long as it remains within realistic limits (more than
0—98%). Given the shorter duration of passive immunity in
ewborns to vaccinated mothers, more infants less than 15
onths old will experience a larger period during which the
iter of maternal antibodies falls below a protective level.
t 10 months of age, for example, the prevalence of suscep-
ible children is expected to increase from 87% to 93% andJVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
6%, respectively in the cohorts of 1998, 2010, and 2028. 457
If vaccination coverage decreases to levels around 90%, 458
nticipation of the age from 15 to 12 months of age should 459
ecrease Re below 1 and avoid outbreaks. For higher levels of 460
accination coverage, if indigenous measles remains absent, 461
igure 8 Evolution between 1967 and 2036 of the proportion
f newborns born to vaccinated mothers. Proportions were cal-
ulated based on model simulations where different vaccination
overages are considered.
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he system will reach a state where every newborn child will
e born either to a vaccinated or to a susceptible mother.
n such a limit situation, the anticipation of the age of MMR
from 15 to 12 months of age should decrease the number
f susceptible infants per day in about 25% (assuming Type
mortality and average duration of passive immunity of 3
onths). We have found that this is not an important deter-
inant for sustained measles elimination in Portugal, but
t would reduce the likelihood of infants being involved in
ocalized outbreaks triggered by imported cases of measles.
onclusions
he vaccination coverage in Portugal increased consistently
ince 1974, as the number of vaccines given over time
ncreased and the yearly number of newborns decreased
Fig. 1). Vaccination coverage per cohort, evaluated at 2
ears of age, was estimated to rise from about 20% in 1974
o current levels at about 95% (Fig. 2). The peak vaccine
ptakes observed shortly after 1985, 1989, and 1994 (Fig. 1),
robably in reaction to the epidemic outbreaks that took
lace those years, are also a likely consequence of the new
accination schemes introduced in 1987 (monovalent vac-
ine was substituted by the MMR) and 1990 (the two-dose
cheme began).
The age-structured seasonally-forced model presented
ere, has the capability to reconstruct the epidemiologi-
al patterns of measles incidence in Portugal during the
ost recent decades, given the appropriate set of basic
eproduction numbers and plausible assumptions about
ow vaccination was distributed over ages and time. The
odel reproduces the pre-vaccination 3-year inter-epidemic
eriod, which had previously been reported from time series
nalysis of deaths by measles [32], as well as the major
utbreaks that took place in 1984—1985, 1988—1989, and
993—1994. As expected, the absolute number of cases
ver time, predicted by the model, is much larger than
he number of measles notiﬁcations reported to authorities
n Portugal. Indeed, the model suggests that notiﬁcations
nderestimate the number of cases by a factor of seven. This
gure is coincident with the conclusion by Fleming et al. [36]
hat chickenpox incidence is seven times higher than the
umber of notiﬁcations reported by the Portuguese sentinel
urveillance network.
The distribution of seropositives by age (>2 years old)
roduced by the model is in good agreement with results of
he NSS based on blood samples collected in 2002 (Fig. 4B).
oth show that the most prominent pool of susceptibles is in
he 1978—1982 cohorts (20—24 years of age in 2002), with
n estimate of 10% and 14% susceptibles, respectively, in
he model and in the NSS. Cohorts from 1974, the year that
orrespond to the introduction of vaccination, until 1983
ere shown to have low vaccination coverages (Fig. 1) which
llied to smaller outbreaks (Fig. 3) cause this increase in sus-
eptibility. Nonetheless, during the years from 1974 to 1977,
here was supplementary vaccination due to the catch-upU
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ampaign held between 1973 to 1977, making this cohorts
ess susceptible then the 1978 to 1982 ones.
The model indicates that the 1998—1999 catch-up cam-
aign, put into place by health authorities to avoid an
utbreak projected for 1999—2000, created conditions to
A
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ring the effective reproduction number of measles to val-
es continuously below 1. The simulations thus support the
laim that the reduced notiﬁcation of suspected cases of
easles in Portugal since 2002, and the absence of labora-
ory conﬁrmed cases, is a consequence of the interruption
f indigenous measles transmission in Portugal since the late
990s.
Outbreaks linked to imported cases are likely to continue
o occur as long as measles remains endemic in parts of
he world. Importations to well immunized countries will
ffect susceptible infants and previously vaccinated individ-
als whose immunity may not be complete. The capacity to
eep imported cases from triggering endemic disease resur-
ence, is very much dependent on our ability to maintain a
ery high level of vaccination coverage (>95%) with the MMR
. This conclusion remains valid, irrespective of whether the
accine is given at 12 or 15 months, and is little sensitive
o changes in realistic levels of vaccination coverage with
he MMR II. It is also in agreement with previous theoretical
esults on how crucial it is to keep high levels of ﬁrst-dose
overage in two-dose vaccination schemes against childhood
iseases [19].
The anticipation of the age of the MMR I has a signiﬁcant
mpact on global transmission levels for a narrow band of
accination coverage around 90%. Below this level of vac-
ination Re will be above 1 irrespective of whether the age
or MMR I is anticipated or not. Also if the level of vaccina-
ion coverage is above this band the reproduction number is
lways below 1. This result differs from other authors [37]
ho considered the contact rate in the ﬁrst age group (0—4
ears old) the lowest one. In our case this is the second high-
st contact rate, which is in accordance with the high rates
f attendance of very young infants (from 4 months old) to
aycare centers in Portugal.
In conclusion, Portugal is expected to remain free of
ndemic measles transmission if the present social and
emographic conditions are maintained and levels of vacci-
ation coverage with the MMR I remain above 95%, together
ith timeliness in the application of the recommended
chedule. The greatest threat to measles elimination in
ountries like Portugal is reduced compliance with vaccina-
ion in face of a false sense of security created by absence of
ublicized outbreaks over the years. The longer the commu-
ity goes without circulating measles virus, the more strict
ublic health ofﬁcials must be in handling imported cases
nd ﬁghting the tendency to lower defences against what
ight become perceived as a disease of the past to the eyes
f health workers and the general public.
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ppendix A. Model description 575
e have used an age-structured model with six epidemio- 576
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Dynamics and control of measles in Portugal
into newborns to vaccinated mothers (M) and newborns to
naturally immune mothers (P), susceptibles (S), exposed (E),
infectious (I), and recovered (R) individuals. Newborns enter
cohorts deﬁned by the academic year (1st October to 30th
September), moving altogether to the next year of age at
the beginning of a new academic year. A total of 75 cohorts
were initiated with n0 = 126, 666 newborns. Those born to
susceptible mothers enter directly into the susceptible com-
partment, whereas newborns with passive immunity enter
the appropriate maternally protected compartment. The
model keeps track of daily changes of individuals between
epidemiological compartments throughout the year, using a
4th order Runge—Kutta approximation. The simpliﬁed model
equations used throughout the whole school year are formal-
ized as
For i = 0, 1
dPi
dt
= −pPi
dMi
dt
= −mMi
dS0
dt
= −(a, t)S0 + pP0 + mM0
dS1
dt
= −(a, t)S1 + pP1 + mM1 − ϕ1S1
for i = 2, . . . , 74
dSi
dt
= −(a, t)Si − ϕiSi
else, for i = 0, . . . , 74
dEi
dt
= (a, t)Si − Ei
dIi
dt
= Ei − Ii
dRi
dt
= Ii
dVi
dt
= ϕiSi
Initial conditions are deﬁned every year as:
P0 = no − (
∑
i
fiSi +
∑
i
fiVi)
M0 =
∑
i
fiVi
S0 =
∑
i
fiSiU
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Also,
E0(0) = I0(0) = R0(0) = V0(0) = 0 and
Pi(0) = Mi(0) = Si(0) = Ei(0) = Ii(0) = Ri(0) = Vi(0) = 0
t
a
a
t
w P
RO
OF
 PRESS
9
fter running the differential equations for 365 days, the
nitial values are update as:
P1(0) = P0(365)
M1(0) = M0(365)
or i = 2, . . . , 74
i(t) = Mi(t) = 0
nd for i = 1, . . . , 74
Si(0) = Si−1(365)
Ei(0) = Ei−1(365)
Ii(0) = Ii−1(365)
Ri(0) = Ri−1(365)
Vi(0) = Vi−1(365)
ere m and p are the rates of loss of protection by mater-
al antibodies in newborns to, respectively, vaccinated and
aturally immunized mothers. Individuals leave the suscep-
ible compartment either by vaccination at rate ϕi, that
epends on age a and time t, or by infection at a rate deﬁned
y the force of infection (a, t). Once infected, individuals
ecome latent and then infectious at rate , recovering from
nfectiousness at rate . Individuals who become immune,
ither by vaccination or natural infection, are assumed to
tay immune lifelong. Numerical values for the parameters
re listed in Table 2.
The force of infection is deﬁned by the function,
(a, t) =
4∑
a=1
b(a)I(a, t) (A.1)
here b(a) is the age-related transmission rate (number of
ontacts per unit time). I(a, t) is the number of infectious
ndividuals in age group a at time t. Age groups are deﬁned
s 0—4, 5—10, 11—20 and more then 20 years. The force
f infection depends on the WAIFW (Who Acquires the Infec-
ion From Whom) matrix, a way of representing assumptions
bout how individuals mix among ages [24,28]. We have used
WAIFW matrix that conveys the common opinion that the
ain route of transmission takes place in primary schools
5—10 years old children). The structure of theWAIFWmatrix
as deﬁned as in Schenzle [24] and Anderson and May [28],
AIFW =
⎛
⎜⎜⎝
b(1) b(1) b(3) b(4)
b(1) b(2) b(3) b(4)
b(3) b(3) b(3) b(4)
b(4) b(4) b(4) b(4)
⎞
⎟⎟⎠
here is a unique coefﬁcient (b(2)) describing the transmis-
ion among susceptible and infectious in age group 2 and
here are two other coefﬁcients, b(1) and b(3), for the con-JVAC 7879 1—10
namics and control of measles in Portugal: Accessing
MMR from 15 to 12 months of age, Vaccine (2008),
acts among individuals aged less then 21 years; whereas 638
dults are described as being likely to acquire infection from 639
wider range of age groups. We further use a symmetry rela- 640
ion, indicating that individuals in age group j make contact 641
ith individuals in age group i at the same rate as individuals 642
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0
n the latter group make contact with those in the former.
ransmission in the 5—10 age group, b(2), takes a minimum
alue (equal to b(1)) every Sunday, during Christmas holi-
ays (23rd of December to January the 7th), Easter holidays
11th to 25th of April) and during the summer holidays (14th
f July to the 7th of October). The set of values used for the
AIFW matrix elements are in Table 3.
The adopted structure ﬁts the pattern found by Del Valle
t al. [?] when studying contact patterns that determine the
ransmission of air born diseases.
To compute the number of newborns through time as a
unction of women’s age, we have used the fertility function
i estimated for Portugal in 1994 [26], deﬁned as the average
umber of children per women at age i.
We assumed that all individuals die as they reach the age
f 75 years (type I mortality).
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